# Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT07115485** · PHASE2 · RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 60 (estimated)

## Conditions studied

- Gastric or Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** HLX43 DOSE 1
- **DRUG:** HLX43 DOSE 2
- **DRUG:** HLX43 DOSE 3

## Key facts

- **NCT ID:** NCT07115485
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2027-08-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07115485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07115485, "Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07115485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*